Arlington Partners LLC Has $4.56 Million Stock Position in Novo Nordisk A/S $NVO

Key Points

• Arlington Partners LLC increased its stake in Novo Nordisk A/S by 33.9% in the 2nd quarter, now owning 66,078 shares valued at approximately $4.56 million.
• Several large investors have significantly modified their holdings in the company, with Kingstone Capital Partners Texas LLC increasing their position by over 301,000% during the same period.
• Novo Nordisk A/S reported an EPS of $0.97 for the latest quarter, surpassing analyst expectations of $0.93, alongside a net margin of 35.60% on revenue of $11.69 billion.

Arlington Partners LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 33.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 66,078 shares of the company's stock after buying an additional 16,733 shares during the period. Novo Nordisk A/S makes up approximately 1.7% of Arlington Partners LLC's holdings, making the stock its 18th biggest holding. Arlington Partners LLC's holdings in Novo Nordisk A/S were worth $4,561,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Hawaiian Bank raised its holdings in shares of Novo Nordisk A/S by 0.6% in the first quarter. First Hawaiian Bank now owns 22,401 shares of the company's stock valued at $1,556,000 after purchasing an additional 142 shares during the last quarter. Anchor Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 1.1% in the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company's stock valued at $944,000 after buying an additional 150 shares in the last quarter. Xponance Inc. increased its holdings in Novo Nordisk A/S by 5.0% during the first quarter. Xponance Inc. now owns 3,314 shares of the company's stock worth $230,000 after buying an additional 158 shares during the last quarter. Foster Dykema Cabot & Partners LLC raised its position in Novo Nordisk A/S by 3.8% during the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company's stock worth $319,000 after acquiring an additional 166 shares in the last quarter. Finally, 180 Wealth Advisors LLC lifted its stake in Novo Nordisk A/S by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock valued at $348,000 after acquiring an additional 173 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NYSE:NVO traded down $0.70 during trading hours on Monday, reaching $60.70. 10,729,184 shares of the company were exchanged, compared to its average volume of 13,091,512. The business has a 50 day moving average of $56.71 and a 200 day moving average of $64.92. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $127.61. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company has a market capitalization of $271.03 billion, a P/E ratio of 16.68, a P/E/G ratio of 2.33 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 22.53%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Barclays reissued an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Hsbc Global Res cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $81.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.